Intrinsiqq
Enveric Biosciences Inc. logo

Enveric Biosciences Inc.

ENVB

⊜ Compare

Company Information We were incorporated under the laws of the State of Delaware in February 1994 as Spatializer Audio Laboratories, Inc., which was a shell company immediately prior to the completion of a reverse merger transaction on May 26, 2015, whereby Ameri100 Acquisition, Inc., a Delaware corporation and newly created, wholly owned subsidiary, was merged with and into Ameri and Partners …

Valuation & Multiples

Based on TTM earnings · Diluted shares

Market Cap$7M
EPS-$11.85
P/E-0.12
P/FCF-0.76
EV/EBITDA0.20
FCF Yield–
Div. Yield–
Net Debt/FCF1.0x
Enveric Biosciences Inc. intrinsic value
52-Week Range
$1.27$4.26

Profitability & Returns

Revenue

N/A

Net Income (TTM)

-$9M

▲ +8.4% YoY

Op. Margin

–

ROIC

-132.75%

▲ +188.6pp YoY

Cash Flow & Balance Sheet

FCF (TTM)

-$9M

▼ -5.4% YoY

Op. Cash Flow (TTM)

-$9M

▼ -5.4% YoY

Net Debt

-$8M

Net Cash Position

Cash & Equiv.

$8M

Continue Research

Peers

Pharmaceutical Preparations · Pick stocks to compare with ENVB

CompareIntrinsic value
EQEquillium, Inc.
$1.40-0.71%40
NERVMinerva Neurosciences Inc.
$2.57+9.36%10
LXRXLexicon Pharmaceuticals, Inc.
$1.48+1.37%40
CRNXCrinetics Pharmaceuticals Inc.
No recent price40
CUECue Biopharma, Inc.
$19.84-4.89%40
ZYMEZymeworks Inc.
$30.98+2.82%10
WVEWave Life Sciences Ltd.
$3.62+1.12%40
ZOMDFZomedica Corp.
$0.09-1.08%46

Held by ETFs

ENVB is in 1 US ETF. The largest of them, with ENVB's weight in each:

Enveric Biosciences (ENVB) in three numbers

Quality score
21/100
Best check: net debt, -$8M. Weakest: return on capital, -132.8%.
Quality
Dividend
None
No dividend in the SEC filings we hold.
Dividends
P/E
-0.12
Negative: a loss over the last twelve months. Price to free cash flow -0.76.
Financials

Questions about Enveric Biosciences

Is Enveric Biosciences a high-quality business?

Enveric Biosciences scores 21 out of 100 on Intrinsiqq's quality score, which makes it a lower-quality business on these measures. The score blends 6 checks computed from SEC filings. Its best check is net debt at -$8M, and its weakest is return on capital at -132.8%. The Quality tab shows every check against its target.

Does Enveric Biosciences (ENVB) pay a dividend?

No. Enveric Biosciences (ENVB) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.

Source: 10-Q filed 12 Aug 2026 (period ending 30 Jun 2026), SEC. Price: last close 4 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.

Spot a number that looks wrong? Check it in ENVB's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing ENVB

Create a free account and get 14 days of Premium: every stock and every tool.

  • Unlimited stocks
  • Stock screener
  • Portfolio tracker
  • Editable DCF
  • Compare side by side
  • Unlimited alerts

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

SectorsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.